Currently, the global biopharmaceutical industry is in a period of rapid expansion. The aging population and increased health awareness among residents have driven a surge in demand for treatments in areas such as oncology and autoimmune diseases. Biopharmaceuticals, with their excellent efficacy and safety, have become a core growth area of the market. Against this backdrop, the outsourcing (CRO) industry for pharmaceutical research and development has exploded, with pharmaceutical companies outsourcing R&D processes to reduce costs and improve efficiency. Chinese CRO companies have risen rapidly relying on their advantages. Antibody drugs, as a core segment of biopharmaceuticals, are booming with innovative categories emerging and key technologies driving them towards higher safety and efficacy.
Since the first monoclonal antibody was approved in 1986, the antibody drug market has gone through a development process from murine antibodies to fully humanized antibodies. The global therapeutic antibody market had a compound annual growth rate of 10.5% between 2019 and 2024, and is expected to have a compound annual growth rate of 8.0% between 2024 and 2031. The Chinese therapeutic antibody market had a compound annual growth rate of 35.4% between 2019 and 2024, and is expected to have a compound annual growth rate of 19.2% between 2024 and 2031. Fully humanized antibodies are becoming a trend in the future antibody drug market due to their lower immunogenicity.
The 'Preclinical Research and Development Services Market Report on Innovative Drugs' mainly focuses on the development trends of the global and Chinese biopharmaceutical markets, a detailed introduction to CRO (Contract Research Organization) services, the development history and future trends of the antibody drug market, as well as the competitive landscape of the preclinical pharmacodynamic evaluation service market in China.
